REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/13/2026
Back to search
Official data from USPTO
VAXXAS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
VAXXAS
ST13
US500000079287747Class
5, 10, 40, 42, 44, 45
Filing
79287747
Registration
6413534
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
07/13/2026
Trademark type
Word
Nice classes
5, 10, 40, 42, 44, 45
Filing date
04/20/2020
Registration date
07/13/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/13/2021
Last transaction
07/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Sydney, NSW, AU
Examiner
LEASER, ANDREW C
Law office
M80
Current location
TMO LAW OFFICE 117
Holders and representatives
Holders
Vaxxas Pty Ltd
Vaxxas Pty Ltd
Representatives
Gregory M. Krakau Krakau Law, P.C.
Technical classification
Nice Classes
Class 5Class 10Class 40Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalmedicinal and therapeutic preparations for human and veterinary use for the treatment of infectious diseaseallergies and oncology; vaccines; vaccine preparations; diagnostic preparations for medical or veterinary purposes; biological specimensblood and plasma for human medical diagnostics and analysis; transdermal patchesbandagespoultices and medical dressings impregnated with vaccines; patchesbandagespoultices and medical dressings impregnated with vaccines; transdermal vaccine delivery system being patches for administering vaccines; pharmaceutical preparations for treating infectious diseaseallergies and oncology contained in transdermal patches; skin patches for the transdermal delivery of pharmaceuticals for use in the treatment of infectious diseaseallergies and oncology; transdermal patches for administering pharmaceuticals for use in the treatment of infectious diseaseallergies and oncology and vaccines; intradermal patches for use in the medical treatment of infectious diseaseallergies and oncology; intradermal vaccine delivery system being patches for administering vaccines; pharmaceutical preparations contained in intradermal patches for use in the medical treatment of infectious diseaseallergies and oncology; skin patches for the intradermal delivery of pharmaceuticals for use in the treatment of infectious diseaseallergies and oncology; intradermal patches for medical treatment for administering pharmaceuticals for use in the medical treatment of infectious diseaseallergies and oncology and vaccines; micro-projection array patches for medical purposes impregnated with vaccines; structural parts and fittings for the aforesaid goods
Class 10
Surgical and medical apparatus and instrumentsvaccine and drug delivery microneedle array patches sold without medication; drug delivery devices and apparatushermetically sealed applicators containing patches for applying vaccine sold without medication; drug delivery devices sold emptyuncoated patches sold without medication; transdermal drug delivery devices and apparatustransdermal drug delivery patches sold without medication; intradermal drug delivery devices and apparatusintradermal drug delivery patches sold without medication; micro-projection drug delivery devices and apparatusdrug delivery patches sold without medication; structural parts and fittings for the aforesaid goods
Class 40
Custom manufacturing services in the field of drug delivery patches; custom manufacture of medical devicespharmaceuticalsdiagnostic tests and testing kits; custom manufacture of micro-projection array patches; custom manufacture of drug delivery devices and apparatus; custom manufacture of transdermal drug delivery devices and apparatus; custom manufacture of intradermal drug delivery devices and apparatus; custom manufacture of micro-projection drug delivery devices and apparatus; advisoryconsultancy and information services in relation to all of the aforesaid
Class 42
Researchdesign and development services in the field of medical apparatus and instruments; medical researchdesign and development services in the field of drug delivery devices; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; drug discovery; vaccine screeningsafety testing of vaccines; scientific and technological research services related to immunopharmaceuticals and vaccines; biological researchclinical research in the field of immunologyvaccinesmedical research; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical and biochemical analysis services; medical and scientific research; pharmaceutical research services; laboratory testing services in the field of vaccinespharmaceuticals; laboratory research in the fields of biotechnologymicrobiologymolecular biologynanotechnology analytical chemistrybiochemistrymedicinal chemistry and drug development; technology servicesdesign and development of computer hardware; scientific researchclinical researchdevelopmentadvisory and consultancy services in relation to antibody production; research and development services in the field of antibodies; antibody generation services being research and development services; diagnostic and research services and screening in the field of infectious diseaseallergies and oncology for medical research purposes; diagnostic testing services in the field of medical apparatus and instruments; medical research services; advisory services relating to diagnostic testing of products for quality control and safety purposes; research and development of products; advisoryconsultancy and information services in relation to all of the aforesaid
Class 44
Medicalmedical clinichealthcare services relating to vaccines; medical and veterinary consultancy; medical testing for diagnostic or treatment purposes; advisoryconsultancy and information services in relation to all of the aforesaid
Class 45
Legal services relating to the exploitation and licensing of intellectual property and technology; licensing of medical technology; legal services relating to the licensing of research and development of products; advisoryconsultancy and information services in relation to all of the aforesaid
Publications
History of USPTO decisions and trademark events.
44 publications found
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
10/10/2023
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
09/05/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/30/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/25/2022
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
03/25/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/24/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/28/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/09/2021
FIMP
FINAL DISPOSITION PROCESSED
11/09/2021
ES7R
TEAS SECTION 7 REQUEST RECEIVED
10/31/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/13/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/13/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/27/2021
PUBO
PUBLISHED FOR OPPOSITION
04/27/2021
GPNX
NOTIFICATION PROCESSED BY IB
04/24/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/07/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/23/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/23/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/22/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/22/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/17/2021
GNFR
FINAL REFUSAL E-MAILED
03/17/2021
CNFR
FINAL REFUSAL WRITTEN
03/17/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/23/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/23/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/10/2020
GNRT
NON-FINAL ACTION E-MAILED
09/10/2020
CNRT
NON-FINAL ACTION WRITTEN
09/10/2020
RFNT
REFUSAL PROCESSED BY IB
08/30/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/20/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/19/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/19/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/11/2020
RFRR
REFUSAL PROCESSED BY MPU
08/11/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/20/2020
CNRT
NON-FINAL ACTION WRITTEN
07/19/2020
DOCK
ASSIGNED TO EXAMINER
07/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
06/24/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/20/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/18/2020
Continuous trademark protection
Get notified about every new filing that threatens VAXXAS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.